Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wooldridge, J.
Right arrow Articles by Moreno, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wooldridge, J.
Right arrow Articles by Moreno, L.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 17, Issue 6 541-547, Copyright © 1994 by American Diabetes Association


ARTICLES

Evaluation of the costs to Medicare of covering therapeutic shoes for diabetic patients

J Wooldridge and L Moreno
Mathematica Policy Research, Princeton, New Jersey 08543-2393.

OBJECTIVE--A three-year demonstration was fielded in three states to evaluate the cost to Medicare of a therapeutic shoes benefit for Medicare Part B beneficiaries with severe diabetic foot disease. RESEARCH DESIGN AND METHODS--Eligible Medicare beneficiaries who applied were randomly assigned to either a treatment group that received the extra therapeutic shoe coverage or a control group that received only standard Medicare coverage. This study analyzes the Medicare payments and service use of 3,428 demonstration participants in California, Florida, and New York for whom data on a 12-month follow-up period were available. These results are comparable to those for the entire sample over a variable length follow-up period that averaged 20 months but ranged from 3 months to 3 years. RESULTS--Differences between groups are not statistically significant. However, Medicare payments for all services among the treatment group were $451 (3.8%) higher than those for all services among the control group. Similarly, Medicare payments for foot-care services were $318 (14.6%) higher among beneficiaries in the treatment group, which considerably exceeded the cost of the shoe benefit ($118). CONCLUSIONS--The demonstration produced no definitive evidence that expanding Medicare Part B to cover therapeutic shoes for beneficiaries with severe diabetic foot disease would increase total Medicare costs. However, our findings indicate that the demonstration was successful at increasing therapeutic shoe ownership and was instrumental in increasing beneficiaries' use of the shoes when walking outdoors.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
The Diabetes EducatorHome page
L. A. Valente, M. Caughy, and L. Fischbach
A Validation Study of a Self-Administered Questionnaire to Identify Increased Risk for Foot Ulceration or Amputation Among People With Diabetes
The Diabetes Educator, November 1, 2004; 30(6): 932 - 944.
[PDF]


Home page
Diabetes CareHome page
M. L. Maciejewski, G. E. Reiber, D. G. Smith, C. Wallace, S. Hayes, and E. J. Boyko
Effectiveness of Diabetic Therapeutic Footwear in Preventing Reulceration
Diabetes Care, July 1, 2004; 27(7): 1774 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
J. W. LeMaster, J. R. Sugarman, G. Baumgardner, and G. E. Reiber
Motivational Brochures Increase the Number of Medicare-Eligible Persons With Diabetes Making Therapeutic Footwear Claims
Diabetes Care, June 1, 2003; 26(6): 1679 - 1684.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1994 by the American Diabetes Association.